Petros Pharmaceuticals Inc (NASDAQ: PTPI) has seen a decline in its stock price by -6.40 in relation to its previous close of 0.12. However, the company has experienced a -60.07% decline in its stock price over the last five trading sessions. accessnewswire.com reported 2025-02-18 that NEW YORK, NY / ACCESS Newswire / February 18, 2025 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI) (“Petros” or the “Company”), a company focused on expanding consumer access to medication through over-the-counter (“OTC”) drug development programs, today announces the pricing of a public offering of approximately 40,000,000 shares of the Company’s common stock (“Common Stock”), par value $0.0001 per share (or pre-funded warrants in lieu thereof), with each share of Common Stock (or pre-funded warrant) accompanied by (i) a Series A Warrant to purchase 0.25 share of Common Stock at an exercise price of $0.48 per 0.25 share (“Series A Warrant”) and (ii) a Series B Warrant to purchase one (1) share of Common Stock at an exercise price of $0.48 per share (“Series B Warrant”). The combined public offering price of each share of Common Stock together with the accompanying Series A Warrant and Series B Warrant is $0.24, and the combined public offering price of each pre-funded warrant together with the accompanying Series A Warrant and Series B Warrant is $0.2399, which represents the per share offering price for the Common Stock less the $0.0001 per share exercise price for each pre-funded warrant.
Is It Worth Investing in Petros Pharmaceuticals Inc (NASDAQ: PTPI) Right Now?
Company’s 36-month beta value is 1.96.Analysts have differing opinions on the stock, with 0 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for PTPI is 10.43M, and currently, short sellers hold a 7.01% ratio of that floaft. The average trading volume of PTPI on February 24, 2025 was 5.07M shares.
PTPI’s Market Performance
PTPI’s stock has seen a -60.07% decrease for the week, with a -66.09% drop in the past month and a -53.41% fall in the past quarter. The volatility ratio for the week is 47.29%, and the volatility levels for the past 30 days are at 19.04% for Petros Pharmaceuticals Inc The simple moving average for the past 20 days is -50.64% for PTPI’s stock, with a -68.68% simple moving average for the past 200 days.
PTPI Trading at -61.34% from the 50-Day Moving Average
After a stumble in the market that brought PTPI to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -93.34% of loss for the given period.
Volatility was left at 19.04%, however, over the last 30 days, the volatility rate increased by 47.29%, as shares sank -64.42% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -67.67% lower at present.
During the last 5 trading sessions, PTPI fell by -60.17%, which changed the moving average for the period of 200-days by -83.14% in comparison to the 20-day moving average, which settled at $0.2370. In addition, Petros Pharmaceuticals Inc saw -70.30% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for PTPI
Current profitability levels for the company are sitting at:
- -3.38 for the present operating margin
- 0.73 for the gross margin
The net margin for Petros Pharmaceuticals Inc stands at -2.63. The total capital return value is set at -1.67.
Based on Petros Pharmaceuticals Inc (PTPI), the company’s capital structure generated 0.7 points at debt to capital in total, while cash flow to debt ratio is standing at -0.8. The debt to equity ratio resting at 2.33. The interest coverage ratio of the stock is -26.17.
Currently, EBITDA for the company is -4.21 million with net debt to EBITDA at -3.37. When we switch over and look at the enterprise to sales, we see a ratio of 1.16. The receivables turnover for the company is 2.06for trailing twelve months and the total asset turnover is 0.19. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.85.
Conclusion
In a nutshell, Petros Pharmaceuticals Inc (PTPI) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
